Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Traws Pharma Reports $3.5 Million Third-Quarter Net Loss

None

Traws Pharma (TRAW) reported a third-quarter 2026 net loss of $3.5 million, or $0.18 per basic and diluted common share, compared with a $4.0 million loss in the prior-year quarter. The company reported no revenue for the quarter ended September 30, 2026.

Traws said its final Phase 2a ratutrelvir study supported further evaluation in COVID-19 patients ineligible for PAXLOVID, while its tivoxavir marboxil tablet bridging study and toxicology retesting supported a planned fourth-quarter regulatory resubmission.

  • Cash and cash equivalents were $2.3 million at September 30, 2026, versus $3.8 million at December 31, 2025.
  • Research and development expense was $1.8 million, down from $2.3 million a year earlier.
  • General and administrative expense was $1.8 million, compared with $1.7 million in the prior-year quarter.
  • The company entered a $50 million common-stock purchase agreement with Roth Principal Investments on October 23, 2026; no shares had been sold under the agreement.
  • Traws had 15,368,277 common shares outstanding as of November 13, 2026.
EARLY ACCESS
Receive TRAW Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$TRAW Hedge Fund Activity

We have seen 12 institutional investors add shares of $TRAW stock to their portfolio, and 18 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles